Takeda seals a $1.2 billion upfront deal with Innovent Biologics for late-stage cancer therapies, positioning to expand its oncology pipeline and offset patent losses.
October 22, 2025
Source:
Takeda Pharmaceutical Company
Takeda Partners With Innovent Biologics
Major Oncology Pipeline Expansion
Takeda will pay $1.2 billion upfront, including a $100 million equity investment, to partner with China-based Innovent Biologics on three late-stage cancer drugs. The agreement grants Takeda exclusive rights outside Greater China to two late-stage immuno-oncology (IO) and antibody-drug conjugate (ADC) therapies, with an option for a third candidate. If all milestones are met, the overall value could surpass $11 billion (EndPoints News, Fierce Pharma).
Innovent receives $1.2 billion now, including a premium stock investment
Milestones could yield up to $10.2 billion more
Focus is on next-generation therapies for solid tumors
Keep up with the story. Subscribe to the PR+ free daily newsletter
Source:
Takeda Pharmaceutical Company
Financial and Strategic Framework
Terms and Industry Context
The deal involves a 60/40 U.S. profit split on IBI363, one of the late-stage drug candidates. Takeda is responding to recent patent expirations—such as Vyvanse—and reshaping its pipeline, emphasizing promising oncology assets from Chinese biotech firms (BioPharma Dive).
The cancer therapies licensed target major unmet needs in solid tumors
Takeda continues its expansion into Chinese-developed drug portfolios, building on prior deals with companies like Hutchmed
Innovent will focus on maximizing global impact for its therapies
"This deal gives us strong late-stage assets and deeper roots in China’s biotech sector," said Takeda’s CEO.
Read More
Source:
Takeda Pharmaceutical Company
Share this news:
